A Multicentre Study of Patient Survival, Disability, Quality of Life and Cost of Care: Among Patients with AIDS in Northern Italy

PharmacoEconomics

Volumn 22, Issue 1, 2004, Pages 43-53

  Tramarin, Andrea ^a   Campostrini, Stefano ^b   Postma, Maarten J ^c   Calleri, Guido ^d   Tolley, Keith ^e   Parise, Nicoletta ^b   De Lalla, Fausto ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d AMEDEO DI SAVOIA HOSPITAL   (Italy)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DISABILITY; DISEASE SEVERITY; EMOTION; FEMALE; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATION; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISABLED PERSONS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; ITALY; MALE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0442291754     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422010-00004     Document Type: Article

References (28)

1. Hanvelt RA, Ruedy NS, Hogg RS, et al. Indirect costs of HIV/AIDS mortality in Canada. AIDS 1994; 8: 7-11
2. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997; 11: 101-5
3. Palella FJ, Delanee KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
4. Gebo KA, Chaisson RE, Folkemer JG, et al. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-9
5. Keiser P, Kvanli MB, Turner D, et al. Protease inhibitors therapy is associated with decreased with HIV related health care costs in men treated at a Veteran Administration Hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 28-33
6. Perdue BE, Weidle PJ, Everson-Mays, et al. Evaluating the cost of medications for ambulatory HIV-infected persons associated with landmark changes in antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 4: 354-60
7. Lapins D, Hamel E, Barret J, et al. Cost of HIV care in the era of combination therapy [abstract PO 460-737]. 39th ICAAC; 1999 Sep 26-29; San Francisco
8. Moore RD. Cost-effectiveness of combination HIV therapy: 3 year later. Pharmacoeconomics 2000; 17 (4): 325-30
9. Grimes DA, Schultz KF. Bias and causal associations in observational research. Lancet 2002; 359: 248-52
10. Tramarin A, Tolley K, Campostrini S, et al. Efficiency and rationality in the planning of health care for people with AIDS: an application of the balance of care approach. AIDS 1997; 11: 809-16
11. Aggiornamento dei casi di AIDS notificati in Italia al 30 Giugno 2000. Notiziario dell'Istituto Superiore di Sanità 2000; 13 (11): 1-12
12. Alonso J, Hunt S, Niero M, and the European Group for Quality of Life and Health Measurement. European guide to the Nottingham health profile. D Bucquet, editor. France: Montpellier, 1992
13. Wilking D, Thompson C. User's guide to dependency measures for elderly people: social service monograph 1989. Sheffield: Joint Unit for Social Services Research, University of Sheffield, 1989
14. Postma MJ, Jager JC, Ruwaard D, et al. Disease-staging for modelling current and future health-care impact of disease; illustrations for diabetes mellitus and AIDS. Health Policy 1998; 43: 45-54
15. Turner BJ, Kelly JV, Ball JK. A severity classification system for AIDS hospitalisations. Med Care 1989; 27: 423-36
16. Kelly JV, Ball JK, Turner BJ. Duration and costs of AIDS hospitalisation in new york: variations by patients severity illness and hospital type. Med Care 1989; 27: 1085-98
17. Scitovsky AA. Studying the cost of HIV-related illnesses: reflection on the moving target. Milbank Q 1989; 673: 18-44
18. Miners AH, Sabin CA, Trueman P, et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001; 2 (1): 52-8
19. Cook J, Dasbach E, Coplan P, et al. Modelling the long term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses 1999; 15 (6): 499-508
20. Paul S, Gilbert HM, Ziecheck W, et al. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999 Feb 25; 13 (3): 415-8
21. Garanttini L, Tediosis F, Di Cintio E, et al. Resource utilisation and hospital costs of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 2001; 13 (6): 733-41
22. Johnson AM, Shergold C, Haekins A, et al. Patterns of hospital care for patients with HIV infection and AIDS. J Epidemiol Community Health 1993; 47: 232-7
23. Beck EJ, Kennelly J, McKevitt J, et al. Changing use of hospital services and costs at a London AIDS referral centre. AIDS 1994; 8: 367-77
24. Taroni F, Anemona A per il gruppo di Studio AN. CO. L'assistenza ospedaliera per i pazienti con AIDS in Italia. GIAIDS 1993; 1: 2-15
25. Torti C, Casari S, Palvarini L, et al. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmacoeconomic implications in a population-based setting. Health Policy 2003 Sep; 65 (3): 261-7
26. Nieuwkerk PT, Gisolf EH, Colebunders R, et al. Quality of life in asymptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. AIDS 2000; 14: 181-2
27. Revicky DA, Moyle G, Stellbrink HJ, et al. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavirzidovudine and saquinavir-zalcitabine-zidovudinetherapy for HIV-infected adults with CD4 cell count between 50 and 350 per cubic millimeter. AIDS 1999; 13: 851-8
28. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312; 1215-8